Tinlarebant moves closer to FDA review after Belite Bio finishes DRAGON II trial enrollment
Find out how Belite Bio’s DRAGON II milestone moves tinlarebant closer to FDA review as a potential first therapy for Stargardt disease.
LUCE-1 Phase 1/2 study fully enrolled as AAVantgarde evaluates AAVB-081 gene therapy in Usher syndrome type B retinitis pigmentosa
Find out how AAVantgarde Bio’s fully enrolled LUCE-1 Phase 1/2 trial advances AAVB-081 gene therapy development for Usher syndrome-related retinitis pigmentosa.